BORTEZOMIB

Post-LOE

bortezomib

Dr. Reddy's Laboratories

ANDAINTRAVENOUS, SUBCUTANEOUSINJECTABLE

Approved

Jul 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

BORTEZOMIB (bortezomib) by Dr. Reddy's Laboratories is proteasome inhibitors [moa]. Approved for myeloma, lymphoma, myeloma and 1 more indications. First approved in 2022.

Drug data last refreshed 19h ago

Mechanism of Action

Proteasome Inhibitors

Pharmacologic Class:

Proteasome Inhibitor

Indications (2)

myeloma lymphoma

Clinical Trials (20)

NCT07709715Phase 3Not Yet Recruiting

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

Started Jan 2027

260 enrolled

Light Chain (AL) Amyloidosis

NCT07901725Phase 3Not Yet Recruiting

Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis

Started Dec 2026

382 enrolled

Newly Diagnosed AmyloidosisAmyloidosis Stage I-IIIA

NCT07903272Phase 3Not Yet Recruiting

A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Started Dec 2026

1,000 enrolled

Multiple Myeloma

NCT07793422Phase 3Not Yet Recruiting

Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis

Started Nov 2026

370 enrolled

Amyloid Light Chain (AL) Amyloidosis

NCT07609706Phase 1Not Yet Recruiting

A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

Started Oct 2026

20 enrolled

Multiple Myeloma

Worked on BORTEZOMIB at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.